Advances in Targeting Growth Factor Signalling in Neuroblastoma and Overcoming Drug Resistance
Cells · 2025
DOI: 10.3390/cells15010004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Karina Ivanenko und 3 weiteren Autor:innen. Beteiligte Einrichtung: Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia. Hauptthemen laut MEDLINE: Neuroblastoma, Drug Resistance, Neoplasm, Signal Transduction, Intercellular Signaling Peptides and Proteins. Die Arbeit nennt 300 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Neuroblastoma is an embryonal tumour that arises from the malignant transformation of neural crest cells and remains one of the deadliest malignancies in children under five. Neural crest development is regulated by dynamic switches in transcriptional programmes, guided by a variety of growth factors. Due to its developmental origin, neuroblastoma is unique in that these tumours often retain overactivation of growth factor signalling, which can be targeted by receptor tyrosine kinase (RTK) inhibitors. However, mutations in kinases, except for ALK, are extremely rare in neuroblastoma. Furthermore, the high degree of intratumoural heterogeneity often renders RTK inhibition ineffective as a monotherapy. For high-risk tumours, which lack effective treatment options, there remains an unmet need for targeted therapies. This review summarises the roles of growth factor receptors in neural crest and neuroblastoma development in light of recent single-cell studies. We provide a systematic overview of RTK inhibitors that can target growth factor signalling in neuroblastoma and detail their current status in clinical development. We also explore the role of intratumoural heterogeneity in resistance to RTK inhibitors, focusing on the adrenergic-to-mesenchymal transition, which drives a switch in growth factor receptor expression. Finally, we discuss strategies to overcome RTK inhibitor resistance by targeting neuroblastoma cell plasticity, disrupting downstream signalling pathways, or inhibiting escape mechanisms from cell death. This review provides a theoretical basis for developing novel combination therapies incorporating RTK inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
- Advanced Engineering School, ITMO University, 192001 Saint-Petersburg, Russia.
ORCID-Profile: Karina Ivanenko, Vladimir Prassolov
Förderung
- Russian Science Foundation
Zitieren
APA
Ivanenko, K., Shaymardanov, R., Prassolov, V., & Lebedev, T. (2025). Advances in Targeting Growth Factor Signalling in Neuroblastoma and Overcoming Drug Resistance. Cells. https://doi.org/10.3390/cells15010004
Vancouver
Ivanenko K, Shaymardanov R, Prassolov V, Lebedev T. Advances in Targeting Growth Factor Signalling in Neuroblastoma and Overcoming Drug Resistance. Cells. 2025. doi:10.3390/cells15010004
BibTeX
@article{Ivanenko2025,
author = {Ivanenko, Karina and Shaymardanov, Ruslan and Prassolov, Vladimir and Lebedev, Timofey},
title = {Advances in Targeting Growth Factor Signalling in Neuroblastoma and Overcoming Drug Resistance},
journal = {Cells},
year = {2025},
doi = {10.3390/cells15010004}
}
EUVIMED